Skip to main content
. 2020 Sep 4;8(9):330. doi: 10.3390/biomedicines8090330

Figure 2.

Figure 2

BAY 41-2272 increased the soluble guanylyl cyclase (sGC) activity and cyclic guanosine monophosphate (cGMP) formation in HSCs. (A) HSCs were preincubated with or without ODQ (1 µM) sGC inhibitor for 15 min and then treated with BAY 41-2272 (0.3–10 µM) in the presence or absence of S-nitroso-N-acetyl penicillamine (SNAP) (0.1 µM) or sodium nitroprusside (SNP) (0.1 µM) NO donors for another 15 min. (B) The cytosolic fractions from HSCs were mixed with or without ODQ (1 µM), BAY 41-2272 (10 µM), SNAP (0.1 µM), and/or SNP (0.1 µM) at 30 °C for 20 min. The cGMP levels were assayed using enzyme immunoassay (EIA) kits. All data are expressed as mean ± SD (n = 4). ** p < 0.01, *** p < 0.001 compared with the basal; # p < 0.05, ## p < 0.01, ### p < 0.001 compared with (A) BAY 41-2272 (10 µM) alone and (B) the corresponding BAY 41-2272 with or without SNAP or SNP.